Related Experiment Video
Updated: Nov 21, 2025
10:33
An Enrichment Method for Small Extracellular Vesicles Derived from Liver Cancer Tissue
Published on: February 3, 2023
1.5K
Extracellular vesicle-transferred long noncoding RNAs in bladder cancer
1Center for Translational Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China; Key Laboratory for Tumor Precision Medicine of Shaanxi Province, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
Clinica Chimica Acta; International Journal of Clinical Chemistry
|January 15, 2021
Summary
Extracellular vesicles (EVs) carrying long noncoding RNAs (lncRNAs) are key in cancer progression. These EV-transferred lncRNAs show promise as noninvasive biomarkers for bladder cancer (BC) diagnosis and therapy.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Extracellular vesicles (EVs) mediate intercellular communication in the tumor microenvironment.
- Long noncoding RNAs (lncRNAs) transferred via EVs play critical roles in cancer development and progression.
- EV-derived lncRNAs are emerging as valuable biomarkers for cancer diagnosis and prognosis.
Purpose of the Study:
- To review and discuss the roles of EV-transferred lncRNAs in various cancers, with a focus on bladder cancer (BC).
- To summarize current detection technologies for EV-transferred lncRNAs.
- To evaluate the diagnostic and prognostic value of EV-transferred lncRNAs in BC using biological fluids.
Main Methods:
- Literature review of studies on EV-transferred lncRNAs in cancer.
- Comparative analysis of diagnostic values of lncRNAs in urine, serum, and plasma for BC.
- Discussion of biofunctional roles and clinical applications of BC-associated EV-lncRNAs.
Main Results:
- EV-transferred lncRNAs are implicated in cancer progression and can be detected in biological fluids.
- Specific EV-lncRNAs demonstrate diagnostic and prognostic potential for bladder cancer.
- Current research highlights diverse detection technologies and therapeutic strategies.
Conclusions:
- EV-transferred lncRNAs represent a novel strategy for noninvasive BC diagnosis and treatment.
- Further research into BC-associated EV-lncRNAs is warranted to explore their full clinical potential.
- These molecules hold significant promise as biomarkers and therapeutic targets for bladder cancer.
Related Concept Videos
02:39lncRNA - Long Non-coding RNAs
9.4K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.4K
02:39lncRNA - Long Non-coding RNAs
3.1K
3.1K
03:18Non-LTR Retrotransposons
12.6K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
12.6K
01:38Intralumenal Vesicles and Multivesicular Bodies
4.3K
Intraluminal vesicles (ILVs) are small vesicles 50-80 nm in diameter formed during the maturation of early endosomes. A specialized endosome containing numerous ILVs is called a multivesicular body (MVB). ILVs contain internalized molecules such as antigens, nucleic acids, proteins, and metabolites. Some of these molecules are released from the MVBs inside exosomes and are transported to other cells. Other MVBs contain molecules that are retained in the ILVs and are later degraded within the...
4.3K
01:03Rous Sarcoma Virus (RSV) and Cancer
5.8K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
5.8K